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Background. There is little evidence that short-acting opioids as rescue medication for break-
through pain is an optimal long-term treatment strategy in chronic non-malignant pain. We com-
pared clinical studies of long-acting opioids that allowed short-acting opioid rescue medication
with those that did not, to determine the impact of opioid rescue medication use on the analge-
sic efﬁcacy and tolerability of chronic opioid therapy in patients with chronic non-malignant pain.
Methods. We searched MEDLINE (1950 to July 2006) and EMBASE (1974 to July 2006) using
terms for chronic non-malignant pain and long-acting opioids. Independent review of the search
results identiﬁed 48 studies that met the study selection criteria. The effect of opioid rescue
medication on analgesic efﬁcacy and the incidence of common opioid-related side-effects were
analysed using meta-regression.
Results. After adjusting for potentially confounding variables (study design and type of opioid),
the difference in analgesic efﬁcacy between the ‘rescue’ and the ‘no rescue’ studies was not sig-
niﬁcant, with regression coefﬁcients close to 0 and 95% conﬁdence intervals that excluded an
effect of more than 18 points on a 0–100 scale in each case. There was also no signiﬁcant differ-
ence between the ‘rescue’ and the ‘no rescue’ studies for the incidence of nausea, constipation,
or somnolence in both the unadjusted and the adjusted analyses.
Conclusions. We found no evidence that rescue medication with short-acting opioids for
breakthrough pain affects analgesic efﬁcacy of long-acting opioids or the incidence of common
opioid-related side-effects among chronic non-malignant pain patients.
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There is evidence to support the use of opioids for
carefully selected patients with chronic non-malignant
pain.
1 5 28 29 63 An important and controversial issue con-
cerning the management of chronic pain is assessment and
treatment of breakthrough pain. Although there is currently
no unanimous deﬁnition of breakthrough pain in chronic
malignant or non-malignant pain,
64 a consensus panel rec-
ommendation from 2005 suggested that breakthrough pain
should be deﬁned as ‘an abrupt, short-lived, and intense
pain that “breaks through” the around-the-clock (ATC)
analgesia that controls persistent pain’.
6 Subtypes of
breakthrough pain include incident (often predictable and
precipitated by activity or movement), idiopathic or spon-
taneous, and end-of-dose pain.
66 4
Breakthrough pain is best described in patients with
malignant pain, leading to a number of adverse effects
including a more severe pain syndrome.
13 50 52 However,
studies have shown that breakthrough pain is also
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malignant pain conditions and impacts negatively on their
quality of life.
82 44 95 96 67 3In a recent survey of chronic
non-malignant pain, 74% of patients (most commonly, low
back pain) with opioid-controlled baseline pain reported
breakthrough pain, reaching maximum intensity within a
median of 10 min and lasting for a median of 60 min.
49 In
these prevalence studies, the majority of cases of break-
through pain were precipitated (incident pain), although
end-of-dose pain was also reported.
84 95 9It was proposed
recently that peripheral, central, or both sensitization may
be a common component of breakthrough pain in both
malignant and non-malignant diseases.
64
The primary treatment for breakthrough pain in malig-
nant pain is with immediate-release (IR), short-acting
opioids on a pre-emptive or as-needed basis, in addition to
the usual opioid regimen.
73 6This strategy has been
adopted for chronic non-malignant pain. However, there is
little evidence that using short-acting opioids as rescue
medication is an optimal long-term treatment strategy in
chronic non-malignant pain.
Evidence is needed for the routine long-term use of
short-acting opioids for breakthrough pain in patients with
chronic non-malignant pain, particularly as there is a
school of thought that exposure to short-acting opioids
might increase the risk of abuse, opioid tolerance and the
need for dose escalation, or inadequate use of opioids.
These are important unknown factors in our understanding
of opioid usage in pain relief. In addition, many short-
acting opioids are ineffective for certain types of break-
through pain, as their onset of action is outside the
window of maximum pain intensity of the breakthrough
pain episode.
49 50 52 Rapid onset formulations (e.g. oral
transmucosal fentanyl) have been developed to address
this.
36 51 60 62 66 We are not aware of any randomized con-
trolled studies comparing the efﬁcacy and tolerability of
long-acting opioid treatment in chronic non-malignant
pain patients who have access to IR opioids for break-
through pain and those who do not. We have systemati-
cally reviewed the literature to approach this question. We
compared the analgesic efﬁcacy and incidence of common
opioid side-effects between studies of long-acting opioids
in chronic non-malignant pain that did and did not allow
the use of IR opioid rescue medication using meta-
regression analyses.
Methods
The primary objective of this review was to compare clini-
cal studies, in patients with chronic non-malignant pain, of
long-acting opioids that allowed IR opioid rescue medi-
cation (‘rescue’ studies) with those that did not (‘no
rescue’ studies) to determine the impact of opioid rescue
medication use on the analgesic efﬁcacy of chronic opioid
therapy among. As a secondary objective, the impact of
opioid rescue medication use on the tolerability of chronic
opioid therapy in terms of common opioid side-effects
(nausea, constipation, and somnolence/sedation) was also
investigated.
Literature search
The following electronic databases were searched for
articles relevant to this systematic review: MEDLINE (1950
to July 2006) and EMBASE (1974 to July 2006). In the
MEDLINE search, terms for long-acting opioid analgesics
[i.e. (‘analgesics-opioid’, ‘opioid’, ‘narcotic’, ‘fentanyl’,
‘morphine’, ‘hydromorphone’, ‘hydrocodone’, ‘oxycodone’,
‘oxymorphone’, ‘codeine’, ‘dihydrocodeine’, ‘pethidine’,
‘meperidine’, or ‘tramadol’) and (‘delayed-action prep-
arations’, ‘long-acting’, ‘contin’, ‘OROS’, ‘SODAS’,
‘TIMERX’, ‘sustained-release/action’, ‘controlled-release/
action’, ‘delayed-release/action’, ‘extended-release/action’,
‘slow-release/action’, ‘timed-release/action’, ‘modiﬁed-
release/action’, ‘continuous-release/action’, ‘transdermal’,
‘TTS’, ‘TDS’, ‘ER’, ‘CR’, or ‘SR’) or ‘buprenorphine’ or
‘methadone’] were combined with terms for non-malignant
(i.e. ‘noncancer’, ‘nonmalignant’, ‘nononcologic’, ‘nontu-
mour’, ‘multimorbidity’, ‘low back’, ‘chronic musculoskele-
tal’, ‘osteogenic’, ‘phantom limb’, ‘vascular-diseases/
disorders’, ‘chronic pancreatitis’, ‘coronary arteriosclerosis’,
‘coronary atherosclerosis’, ‘neuralgia-postherpetic’,
‘trigeminal-neuralgia’, ‘diabetic neuropathies’, ‘amyloid-
neuropathies’, ‘brachial-plexus-neuropathies’, ‘mononeuro-
pathies’, ‘polyneuropathies’, ‘neuropathy’, ‘neuralgia’,
‘arthritis-rheumatoid’, ‘osteoarthritis’, or ‘osteoporosis’) and
pain (i.e. ‘pain’ or ‘analgesia’) or terms for speciﬁc non-
malignant pain disorders (i.e. ‘low back pain’ or ‘complex
regional pain syndrome’). A number of study design search
terms were also included in the strategy. Equivalent search
terms speciﬁc to EMBASE were used for the EMBASE
search. The full MEDLINE and EMBASE search strategies
are given in Supplementary material, Appendix 1.
All English, German, French, Spanish, or Italian
language full-text research articles were eligible for
inclusion, as long as they met the criteria deﬁned below.
All published, prospective, blinded, or open-label clinical
trials with either a randomized or controlled design were eli-
gible. Prospective observational studies were also accepted.
Case reports, conference proceedings, or retrospective
studies (surveys or audits) were excluded from this review.
Eligible patients were adults aged 18 yr with chronic
non-malignant pain (such as chronic musculoskeletal pain,
vascular disorders, chronic pancreatitis, lower back pain,
osteogenic pain, coronary artery disease, phantom limb
pain, post-herpetic neuralgia, trigeminal neuralgia, diabetic
neuropathy, or neuropathic pain). Studies that included
patients with malignant pain were eligible only if less than
one-third of the study population were patients with malig-
nant pain. Studies in both opioid-naı ¨ve patients and
patients already on opioids were eligible.
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opioids or opioid formulations [such as methadone, trans-
dermal fentanyl, or sustained-release (SR) morphine]
including the weak opioids, tramadol, codeine, and slow-
release dihydrocodeine. All routes of administration, other
than intrathecal or intraspinal, were eligible. Since
intrathecal use of opioids is an invasive method often used
as a last resort in a selection of patients unresponsive to
other treatments, we felt that that patient group is not com-
parable with those receiving oral or transdermal opioids.
All studies in which one or more opioids was administered
for at least 4 weeks, including those that compared one
opioid with placebo, other opioids, or other active controls
were eligible for inclusion. Studies had to have a ﬂexible
dosing regimen (at least during the maintenance phase);
studies with speciﬁc criteria for dose escalation or dose
escalation to a maximum dose were eligible.
Whether an IR opioid was used as rescue medication or
not had to be deﬁned. If this information was not given
explicitly in the publication, a single attempt was made to
contact the authors to obtain this information before the
study was excluded.
Studies reporting at least one of the following outcome
measures were eligible.
(i) A measure of analgesic efﬁcacy, such as pain relief or
pain intensity measured by the Brief Pain Inventory, a
visual analogue scale, or equivalent, or patient and
investigator global assessment of analgesic efﬁcacy.
(ii) Tolerability: number or percentage of patients reporting
either nausea, constipation, or somnolence/sedation (or
drowsiness if somnolence/sedation not reported).
Selection of studies
Titles and abstracts for studies identiﬁed in the literature
search were reviewed for inclusion according to the selec-
tion criteria described above. Those studies that clearly
failed to meet the selection criteria were discarded
immediately. The full-text articles were obtained for all
studies that appeared to meet the criteria and for those
where insufﬁcient information was available in the abstract
to determine eligibility. All full-text articles were reviewed
independently by two reviewers (H.W. and either J.D. or
U.R.) to ensure that all the inclusion criteria were met ade-
quately. Any disagreements between the two reviewers
were resolved by discussion and consensus without the
need to consult a third party. Where it was not clear
whether the use of rescue medication had been allowed
during the study or not, a single e-mail (no reminders) was
sent out to the corresponding author requesting this infor-
mation before the article was excluded. For usual care or
non-interventional trials that did not explicitly report the
use of rescue medication, it was assumed that rescue medi-
cation was allowed as per usual clinical practice.
Eighty-seven potential studies were identiﬁed by
MEDLINE and EMBASE and the full text was reviewed;
of these, 47 were found on closer inspection to meet all
the study selection criteria. The majority of excluded
studies failed to meet more than one of the selection cri-
teria and were therefore not excluded on the basis of one
criterion. Factors commonly leading to exclusion included:
failure to conﬁrm whether opioid rescue medication was
allowed or not, study duration ,4 weeks, incorrect inter-
vention (e.g. intrathecal administration), or inﬂexible
dosing regimen. An additional study
46 that we were aware
was in press at the time of the search and therefore not
picked up by the search strategy was also included, as it
met all the selection criteria.
Data extraction and outcome measures
The following data were extracted from each of the
included studies: study design; type of non-malignant pain
or condition studied; patient numbers; intervention (type
of opioid and route of administration); duration of treat-
ment; the primary or ﬁrst reported (in sufﬁcient detail for
analysis) analgesic outcome (scale, measure at baseline
and endpoint, change in measure or difference vs placebo,
and measures of variation as appropriate); number, per
cent, or both of patients reporting nausea, constipation, or
somnolence/sedation (or drowsiness, if somnolence/seda-
tion not reported); and number or percentage of patients
using rescue medication (for rescue studies only).
We applied the Jadad criteria for randomized controlled
trials to each study to determine the methodological quality
and validity of each study.
25 The criteria were applied inde-
pendently by two reviewers (H.W. and N.M.). There were
three disagreements between the two independent reviewers,
which were resolved by a third party (A.J.).
In brief, a study received one point for each ‘yes’ or
zero points for each ‘no’ given in reply to the questions
provided in Appendix 2 in the Supplementary material
(maximum number of points is 5).
Statistical analysis
The primary outcome was analgesic efﬁcacy and the sec-
ondary outcomes were the percentage of patients with
nausea, constipation, or somnolence. All outcome vari-
ables were analysed in a meta-regression analysis.
68
Meta-analysis would normally be used to investigate the
treatment effect within studies, but since there are no
studies directly comparing the effect of opioid rescue
medication use on long-term analgesic efﬁcacy, we have
used meta-regression to make indirect comparisons
between the ‘rescue’ and the ‘no rescue’ studies.
For the purposes of the analysis, certain study designs
were treated in the following way.
† Studies comparing two long-acting opioids were treated
as two separate uncontrolled studies.
† In two crossover studies comparing transdermal fenta-
nyl with SR morphine, only the experimental
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(AE) analysis (these studies were both excluded from
the primary analysis).
† In studies comparing long- and short-acting opioids, the
long-acting opioid arm was treated as an uncontrolled
study. The rationale for this is that in equivalence
studies of SR opioids, short-acting opioids are often
used to show efﬁcacy of the SR formulation. In these
studies, patients take the short-acting opioids regularly;
therefore, you would expect similar pain control as with
the SR opioid.
† Since placebo-controlled studies often allow continuation
of non-opioid analgesics during the study period, studies
comparing a long-acting opioid with a non-opioid analge-
sic were treated as placebo-controlled studies.
For each study, the primary pain outcome or the ﬁrst pain
outcome reported in sufﬁcient detail was used in the
meta-regression analysis. A measure of the treatment effect,
which was the difference between opioid and control in con-
trolled studies and the difference from baseline in uncon-
trolled studies, was calculated based on the published data.
The standard error (SE) of the treatment effect was also
calculated, using standard formulas if the necessary infor-
mation was available. The following assumptions were
made for uncontrolled studies, if the necessary information
for calculating the SE was not available.
† Mean at baseline or endpoint¼median at baseline or
endpoint.
† Inter-quartile range (IQR)¼1.35standard deviation
(SD) if IQR is speciﬁed and SD is missing.
† If measure of variability of the change was unavailable
and SD of the endpoint value was available, the SD of
the change was assumed to be equal to the SD of the
endpoint value.
The treatment effect for each study was converted where
necessary onto a scale of 0–100 (higher scores equal
worse pain or less pain relief). This was done by multiply-
ing the treatment effect by 100/maximum scale score.
Analgesic effect was analysed in a meta-regression analy-
sis using Stata 9.2.
68 Meta-regression was used to investi-
gate the effect of rescue medication on treatment effect,
while controlling for other potentially confounding vari-
ables, namely study design, Jadad score, and type of
opioid. The regression coefﬁcient from the analysis is the
estimated average difference in analgesic efﬁcacy (number
of points on a 0–100 scale) between the ‘rescue’ and the
‘no rescue’ medication studies; negative values are in
favour of rescue medication. For other variables, negative
scores are in favour of the speciﬁc category in question
and positive values are in favour of the reference category.
The percentage of patients treated with long-acting
opioid with nausea, constipation, or somnolence/sedation
was calculated for each study and the SE of the percentage
was calculated as the width of the exact binomial
conﬁdence interval divided by 21.96 (this is more appro-
priate for small sample sizes than the normal approxi-
mation to the SE). For studies in which the incidence of
AEs was reported separately for different parts of the
study, the highest incidence values were used. As for the
efﬁcacy outcome, meta-regression was used to investigate
the effect of rescue medication, while controlling for other
potentially confounding variables. The logit of the percen-
tage of patients with each AE was also used as a sensi-
tivity analysis, but the results were similar and are
therefore not presented. The logit and SE were calculated
by ﬁtting an intercept-only logistic regression model for
each outcome. The regression coefﬁcient from the analysis
is the estimated average difference in AE incidence (% of
patients) between the ‘rescue’ and the ‘no rescue’ medi-
cation studies; negative values are in favour of rescue
medication. For other variables, negative scores are in
favour of the speciﬁc category in question and positive
values are in favour of the reference category.
The entire analysis was done again, this time excluding
studies with a Jadad score of 0. The analysis was also run
excluding the weak opioids, namely tramadol, codeine,
tilidine, and dihydrocodeine.
In addition, the studies that included any patients with
malignant pain were excluded and the analysis was re-run.
This was done as a sensitivity analysis to ensure that there
was an assessment on pure non-malignant pain.
Results
Study characteristics and quality
Forty-eight studies met all of the study selection criteria
and were included in the review; of these, 24 studies
allowed the use of rescue medication (‘rescue’ studies)
and 24 did not (‘no rescue’ studies). The characteristics of
each included study are summarized in the Supplementary
material.
1–4 9–12 14–16 18–23 27 30–35 37–48 54–58 61 65 67
70–72 75 The frequency of the different types of study
design (for the purposes of analysis), control group (con-
trolled studies only), and opioid type along with the
quality of the included articles in terms of Jadad score is
given for the ‘rescue’ and ‘no rescue’ studies and overall
in Table 1. The maximum time of treatment was 2 yr.
The majority of both the ‘no rescue’ and the ‘rescue’
studies were uncontrolled. All but two of the placebo-
controlled, parallel-group studies and all the crossover
studies (all placebo-controlled) did not allow rescue medi-
cation use. The most common control used in the con-
trolled studies was placebo and the most common opioids
in the ‘no rescue’ group were oxycodone and tramadol
and in the ‘rescue’ group, fentanyl. As may be expected,
there was an imbalance in study quality between the
‘rescue’ and the ‘no rescue’ studies. Most ‘rescue’ studies
were of a low quality (Jadad score of 0 or 1), whereas just
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(Jadad score of 4 or 5). For this reason, Jadad score was
included as a term in the meta-regression analysis.
Of the 24 studies included that allowed short-acting
opioid rescue medication, seven reported the number or
percentage of patients who actually took rescue medi-
cation. In these seven studies, the percentage of patients
who actually took rescue medication ranged from 11% to
100% (median 57%).
11 92 03 33 54 24 5
Analgesic efﬁcacy analysis
Of the 48 studies, 40 were included in the meta-regression
analysis of analgesic efﬁcacy (Table 2). Eight studies were
excluded from the analysis, as it was not possible to calcu-
late either the effect size (n¼4) or the SE for the effect
size (n¼4) based on the published data.
The results of the unadjusted analysis indicated an average
difference of six points on a 0–100 scale for efﬁcacy in
favour of rescue medication use, although this difference
was not signiﬁcant (P¼0.24) (Table 2). As a sensitivity
analysis, studies involving any patients with malignant pain
were excluded and the analysis was re-run. Four studies were
identiﬁed and excluded.
19 21 42 75 After excluding studies
involving any patients with malignant pain, the average
difference was 24.5; 95% CI: 215.38, 6.46; P¼0.424.
After adjusting for potentially confounding variables,
namely study design and both study design and type of
opioid, the difference in analgesic efﬁcacy between the
‘rescue’ and the ‘no rescue’ studies was not signiﬁcant,
with regression coefﬁcients close to 0 and 95% conﬁ-
dence intervals that excluded an effect of more than 18
points in each case. The movement of the regression
coefﬁcient towards 0 after adjustment for study design is
to be expected due to the imbalance in study design
between the ‘rescue’ and the ‘no rescue’ studies.
Excluding studies that involved any patients with malig-
nant pain and adjusting for study design did not affect
the results (regression coefﬁcient 1.2; 95% CI: 210.31,
12.82; P¼0.831). Very similar results were obtained
when the analysis was adjusted for Jadad score and both
Jadad score and study design. This is to be expected, as
Jadad score is a measure of study quality based on the
study design.
Excluding studies with a Jadad score of 0 did not
change the outcome of the analgesic efﬁcacy analysis.
Excluding weak opioids from the analysis also did not
change the ﬁndings.
In the analyses adjusting for study design, a signiﬁ-
cantly greater analgesic effect was seen for uncontrolled
studies vs placebo-controlled, parallel-group studies, as
would be expected (regression coefﬁcient: 216.8; 95%
CI: 230.0, 23.7; P¼0.01). This was also true after adjust-
ing for study design and opioid type. Interestingly, signiﬁ-
cantly better analgesic efﬁcacy was seen in studies of
tramadol compared with morphine studies (regression
coefﬁcient: 221.4; 95% CI: 239.2, 23.5; P¼0.02).
Whether or not opioid rescue medication was allowed
did not signiﬁcantly impact on analgesic efﬁcacy, even
after adjusting for potentially confounding variables (study
design, Jadad score, or study design and opioid type).
Table 2 Analgesic efﬁcacy results.
*Reference category is placebo-controlled.
†Reference category is morphine. CI, conﬁdence interval
Regression
coefﬁcient
95% CI P-value
Unadjusted analysis
Rescue
medication
26.3 216.9, 4.2 0.24
Adjusted for study design
Rescue
medication
20.3 211.6, 11.0 0.96
Uncontrolled
studies*
216.8 230.0, 23.7 0.01
Crossover
studies*
26.9 228.7, 14.9 0.54
Adjusted for study design and opioid type
Rescue
medication
25.2 217.2, 6.9 0.40
Uncontrolled
studies*
216.1 229.6, 22.6 0.02
Crossover
studies*
210.8 232.7, 11.0 0.33
Oxycodone
† 25.6 222.7, 11.5 0.52
Fentanyl
† 22.7 217.7, 12.3 0.73
Tramadol
† 221.4 239.2, 23.5 0.02
Other
† 23.5 220.6, 13.7 0.69
Table 1 Summary of study characteristics and quality.
*How the study was
treated for the purposes of analysis and does not necessarily reﬂect the
original design of the study.
†One study in which the control was
non-steroidal anti-inﬂammatory drug and one study in which the control was
morphine-free patients; both were considered as placebo-controlled studies for
the purposes of the analysis.
‡Controlled studies only (n¼13).
§n¼26 for the
rescue studies, as two of the studies comparing two long-acting opioids were
counted twice; each arm was treated as a separate uncontrolled study
Characteristic No rescue
(n524)
Rescue
(n524)
Total (n548)
Study design*, n (%)
Placebo-controlled crossover 3 (12.5) 0 (0) 3 (6.3)
Placebo-controlled,
parallel-group
†
8 (33.3) 2 (8.3) 10 (20.8)
Uncontrolled 13 (54.2) 22 (91.7) 35 (72.9)
Control group, n (%)
‡
Active placebo 2 (18.2) 0 (0) 2 (15.4)
Morphine-free 0 (0) 1 (50.0) 1 (7.7)
NSAID 0 (0) 1 (50.0) 1 (7.7)
Placebo 9 (81.8) 0 (0) 9 (69.2)
Type of opioid, n (%)
§
Morphine 4 (16.7) 4 (15.4) 8 (16.0)
Oxycodone 6 (25.0) 2 (7.7) 8 (16.0)
Fentanyl 3 (12.5) 13 (50.0) 16 (32.0)
Tramadol 6 (25.0) 1 (3.9) 7 (14.0)
Other 5 (20.8) 6 (23.1) 11 (22.0)
Jadad score, n (%)
0 2 (8.3) 2 (8.3) 4 (8.3)
1 11 (45.8) 21 (87.5) 32 (66.7)
2 0 (0) 1 (4.2) 1 (2.1)
3 0 (0) 0 (0) 0 (0)
4 3 (12.5) 0 (0) 3 (6.3)
5 8 (33.3) 0 (0) 8 (16.7)
Mean (SD) Jadad score 2.6 (2.0) 0.96 (0.36) 1.8 (1.7)
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Twelve studies were excluded from the analysis of nausea,
13 from the analysis of constipation, and 16 from the
analysis of somnolence/sedation, as the data were not
reported.
As for analgesic efﬁcacy, there was no signiﬁcant differ-
ence between the ‘rescue’ and the ‘no rescue’ studies for
the incidence of nausea, constipation, or somnolence
(Tables 3–5) in the unadjusted analysis and after adjusting
for study design and both study design and type of opioid,
with regression coefﬁcients close to 0 and 95% conﬁdence
intervals that excluded an effect of more than about 25%
for nausea, 18% for constipation, and 20% for somno-
lence/sedation. Similar results were seen after adjusting for
Jadad score and both Jadad score and study design (data
not shown).
After adjusting for study design and opioid type, there
was a greater difference in the incidence of nausea
between the ‘rescue’ and the ‘no rescue’ studies in favour
of rescue medication (regression coefﬁcient: 210.9; 95%
CI: 225.4, 3.7; P¼0.14), although the difference was not
signiﬁcant (Table 3).
Studies of fentanyl, tramadol, and ‘other’ opioids
(controlled-release codeine, transdermal buprenorphine,
and slow release tilidine) reported signiﬁcantly less consti-
pation than those of morphine (Table 4). Similarly after
adjusting for study design and opioid type, crossover
studies also reported signiﬁcantly less constipation than
placebo-controlled, parallel-group studies (regression coef-
ﬁcient: 228.2; 95% CI: 250.9, 25.4; P¼0.02; Table 4).
Interestingly, the incidence of somnolence/sedation was
signiﬁcantly higher in the oxycodone studies compared
with the morphine studies (regression coefﬁcient: 20.7;
95% CI: 3.4, 38.0; P¼0.02; Table 5).
Discussion
In patients with malignant and non-malignant chronic pain
treated with ATC opioids, end-of-dose pain is usually
managed by increasing the ATC opioid dose or shortening
the dosing interval, whereas other types of breakthrough
pain are treated with IR short-acting opioids on a pre-
emptive or as-needed basis.
73 6However, there is little
Table 3 Tolerability analysis: nausea.
*Reference category is
placebo-controlled.
†Reference category is morphine. CI, conﬁdence interval
Regression
coefﬁcient
95% CI P-value
Unadjusted analysis
Rescue
medication
24.7 216.2, 6.9 0.43
Adjusted for study design
Rescue
medication
23.8 217.1, 9.6 0.58
Uncontrolled
studies*
22.9 219.1, 13.3 0.73
Crossover
studies*
21.8 227.0, 23.5 0.89
Adjusted for study design and opioid type
Rescue
medication
210.9 225.4, 3.7 0.14
Uncontrolled
studies*
0.13 216.7, 16.9 0.99
Crossover
studies*
24.8 230.0, 20.4 0.71
Oxycodone
† 22.1 222.0, 17.8 0.84
Fentanyl
† 4.5 213.1, 22.1 0.62
Tramadol
† 213.0 233.1, 7.1 0.21
Other
† 218.3 241.3, 4.7 0.12
Table 4 Tolerability analysis: constipation.
*Reference category is
placebo-controlled.
†Reference category is morphine. CI, conﬁdence interval
Regression
coefﬁcient
95% CI P-value
Unadjusted analysis
Rescue
medication
25.5 218.1, 7.2 0.40
Adjusted for study design
Rescue
medication
20.5 215.0, 14.0 0.95
Uncontrolled
studies*
215.1 231.8, 1.6 0.08
Crossover
studies*
214.7 240.3, 11.0 0.26
Adjusted for study design and opioid type
Rescue
medication
22.3 216.8, 12.1 0.75
Uncontrolled
studies*
26.7 221.3, 8.0 0.37
Crossover
studies*
228.2 250.9, 25.4 0.02
Oxycodone
† 5.1 213.1, 23.2 0.58
Fentanyl
† 221.9 238.0, 25.8 0.01
Tramadol
† 227.8 247.1, 28.5 0.01
Other
† 222.2 242.4, 21.9 0.03
Table 5 Tolerability analysis: somnolence/sedation. *Reference category is
placebo-controlled.
†Reference category is morphine. CI, conﬁdence interval
Regression
coefﬁcient
95% CI P-value
Unadjusted analysis
Rescue
medication
20.1 211.3, 11.0 0.98
Adjusted for study design
Rescue
medication
2.9 210.1, 15.9 0.66
Uncontrolled
studies*
28.8 223.9, 6.3 0.26
Crossover
studies*
26.6 229.2, 16.1 0.57
Adjusted for study design and opioid type
Rescue
medication
6.4 26.9, 19.8 0.34
Uncontrolled
studies*
22.9 216.7, 10.8 0.67
Crossover
studies*
215.2 236.3, 5.8 0.16
Oxycodone
† 20.7 3.4, 38.0 0.02
Fentanyl
† 28.5 223.9, 7.0 0.28
Tramadol
† 23.8 221.3, 13.8 0.67
Other
† 22.3 221.6, 16.9 0.81
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581long-term evidence that this is the most appropriate strat-
egy to deal with breakthrough pain in chronic non-
malignant patients. We are not aware of any randomized
controlled studies that have investigated the impact of IR
opioid rescue medication use for breakthrough pain on the
efﬁcacy and tolerability of chronic opioid therapy in
patients with chronic non-malignant pain. In this review,
we have attempted to address this question based on
indirect comparisons between studies of long-acting
opioids in chronic non-malignant pain that allowed the use
of IR short-acting opioids for breakthrough pain and those
that did not.
In the meta-regression analysis, whether or not rescue
medication was allowed did not signiﬁcantly impact on
analgesic efﬁcacy even after adjusting for potentially con-
founding variables, such as study design, Jadad score, and
opioid type. We assumed that rescue medication was used
in studies in which this was not explicitly stated, if they
were usual care or non-interventional studies. The analgesic
effect was signiﬁcantly greater in the uncontrolled studies
than the controlled studies, which is to be expected as
larger effects tend to be seen in uncontrolled studies. These
larger effects are often due to the bias inherent in the study
design, but there is no reason to assume that those biases
are different in rescue vs non-rescue studies. Assuming this
bias to be constant, we did not attempt to adjust for bias in
our analyses, and we do not claim to estimate a valid treat-
ment effect of the opioids under review. These results
suggest that allowing treatment of breakthrough pain with
short-acting IR opioids is of no additional beneﬁt in terms
of long-term analgesic efﬁcacy, but also does not reduce
analgesic efﬁcacy in patients with chronic non-malignant
pain treated with long-acting opioids.
Alternatively, it may be that the IR opioids used in
these studies are not beneﬁcial because their active effect
does not coincide with the peak pain intensity of the
breakthrough pain episode. This would be particularly
important for unpredictable incident pain, which is not
precipitated by a known trigger, and idiopathic or spon-
taneous pain, for which pre-emptive treatment with short-
acting opioids is not possible. The onset of breakthrough
pain in opioid-treated patients with chronic non-malignant
pain is rapid and peaks within a median of 10 min,
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whereas the onset of action of most short-acting opioids is
between 30 and 60 min.
36 As a consequence, the use of
ineffective short-acting opioids may increase their use and
lead to needless escalation in the dose of long-acting
opioids for baseline pain and associated side-effects,
although there is no published literature on this topic to
date. Newer rapid-onset formulations of short-acting
opioids, including oral trans-mucosal fentanyl citrate and
fentanyl buccal tablets, have been shown to be efﬁcacious
for the short-term treatment of breakthrough pain and
well-tolerated among patients with both chronic non-
malignant and malignant pain.
36 51 60 62 74 These studies
speciﬁcally looked at the short-term effects of these
medications on breakthrough pain (up to 2 h after dosing)
and did not address the impact of long-term use of short-
acting opioids for breakthrough pain in addition to a long-
acting opioid regimen on pain control. We were unable to
ﬁnd any studies in malignant pain that directly addressed
the impact of short-acting opioid rescue medication use on
the long-term analgesic efﬁcacy of long-acting opioid regi-
mens. This is not unexpected as malignant pain treatment
is relatively short term and frequent dose adaptations are
necessary owing to the increase in pain.
It is unknown whether long-term use of short-acting
opioids may increase the risk of tolerance and the need for
increasing doses to achieve satisfactory analgesia or increase
the risk of opioid addiction, although there is some evidence
to suggest a link.
26 Although this study was not designed to
speciﬁcally look at tolerance, our results show that overall
analgesic efﬁcacy of an ATC opioid regimen does not
appear to be adversely affected by the availability of short-
acting opioids for rescue medication. This topic is highly
controversial and requires further research.
There was no evidence for an increase or a decrease in
the incidence of the common opioid side-effects such as
nausea, constipation, and somnolence/sedation in studies
that allowed IR opioid rescue medication compared with
those that did not. There was a trend towards a lower inci-
dence of nausea in the rescue medication studies after
adjusting for study design and opioid type, although the
difference was not statistically signiﬁcant. It is possible that
the effect of opioid type was confounding the effect of
rescue medication in the unadjusted analysis. In agreement
with our results, a recent study in malignant pain found no
signiﬁcant differences in the incidence of nausea, consti-
pation, and drowsiness between patients prescribed an ATC
opioid only and those prescribed an ATC opioid plus an
as-needed (PRN) opioid.
69 However, the incidence of these
side-effects was higher in the ATC plus PRN group.
In our analysis, the rate of constipation was signiﬁcantly
lower in the transdermal fentanyl, long-acting tramadol,
and ‘other opioid’ studies than in the studies of long-acting
morphine formulations. In addition, the rate of somnolence
was signiﬁcantly higher in the long-acting oxycodone
studies than in the morphine studies. Previous randomized
studies comparing transdermal fentanyl and SR oral mor-
phine in chronic non-malignant and malignant pain have
shown signiﬁcantly lower rates of constipation with trans-
dermal fentanyl.
121 7Since fentanyl crosses the blood–
brain barrier more rapidly than morphine, it exerts its
analgesic effects at lower doses which have less intestinal
action when compared with morphine.
53 Furthermore, the
transdermal route bypasses opioid receptors in the intes-
tine.
53 The lower rates of constipation in the tramadol and
‘other opioid’ (three of the four studies were with weak
opioids) studies are probably a result of the relatively
weak m-receptor binding in the gut of these weak opioids
compared with morphine. We are unaware of any random-
ized controlled studies comparing long-acting formulations
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582of oxycodone and morphine that show signiﬁcantly higher
rates of somnolence or sedation with oxycodone. The
difference in somnolence rates between the oxycodone and
morphine studies in our analysis is unlikely to be a result
of the over-representation of studies that did not allow
rescue medication among the oxycodone studies, as this
was corrected for in the adjusted analyses, but it may have
been due to the formulation used. OxyContin
w contains an
IR portion and the higher ﬂuctuations in plasma levels of
oxycodone may induce sedation.
As expected, there was an imbalance in study quality
between studies allowing rescue medication use and those
that did not, with more poorer quality studies in the rescue
group. Observational and usual care studies, which are of
lower quality than randomized controlled studies, are less
likely to prohibit rescue medication use. We therefore cor-
rected for study design and Jadad score in the
meta-regression analysis, but results before and after this
adjustment were similar.
It is important to note that our ﬁndings do not imply
that rescue medication is needless. The studies published
to date have not been designed speciﬁcally to address the
topic of rescue medication, and therefore this paper should
only be seen as a review of the ﬁndings to date. More
research is needed in this area to provide a clearer answer.
Ideally, data would be provided from a randomized trial in
which patients have, or do not have, rescue medication
which collects data on pain, tolerability, and dose escala-
tion. In the absence of such a study, we have attempted to
summarize the available literature and make the limitations
of these data clear in our ﬁndings.
Our results do not rule out an effect of opioid rescue
medication on analgesic efﬁcacy or the incidence of
common opioid side-effects, owing to a number of limit-
ations concerning the study design. For the same reason, we
cannot rule out that the higher AE rates associated with
some opioids were due to random variation. The ﬁrst limit-
ation is the heterogeneity of included studies, with a wide
range of study designs, patient populations, and treatment
durations. We have attempted to correct for some, but not
all, of these potentially confounding variables in the
meta-regression analysis. Secondly, the fact that rescue
medication was allowed does not necessarily mean that it
was used and the number or percentage of patients who took
rescue medication was not speciﬁcally or clearly reported in
most of the ‘rescue’ studies. For example, several studies
were usual care studies and rescue medication use was not a
speciﬁc outcome of the study. However, this would be
expected to reﬂect the usual clinical situation, where short-
acting opioids are available for use on an as-needed basis.
Thirdly, although we excluded short-term studies of ,4
weeks, it may be that the studies included in the review
were not sufﬁciently long enough to determine the long-
term effects of using short-acting opioids as rescue medi-
cation in chronic non-malignant pain. Fourthly, the outcome
measure of analgesic efﬁcacy may be too crude to assess
more subtle swings in pain that are nonetheless of clinical
relevance. This is due, at least in part, to the time scale. The
short time window of breakthrough pain may not necessarily
overlap with the time that the pain questionnaire was ﬁlled
out. It is also possible that studies may avoid patients with a
clinical need for short-acting opioids to deal with ﬂares of
pain. Finally, the literature search was not completely sys-
tematic, as our database search was limited to MEDLINE
and EMBASE and we did not include any hand searching. It
is therefore possible that some studies may have been
missed and excluded from the analysis.
Our results do not suggest that treatment of break-
through pain with short-acting IR opioids is of additional
beneﬁt in terms of long-term analgesic efﬁcacy or that it
reduces analgesic efﬁcacy in patients with chronic non-
malignant pain treated with long-acting opioids. There is
also no evidence that allowing opioid rescue medication
use increases or decreases the incidence of the common
opioid side-effects nausea, constipation, and somnolence/
sedation. Compared with morphine studies, the consti-
pation rate was signiﬁcantly lower in the fentanyl, trama-
dol, and ‘other opioid’ studies, and the somnolence rate
was signiﬁcantly higher in the oxycodone studies.
This analysis has tried to collate data from a number of
studies that did not set out to measure rescue medication
as a primary outcome. Taking this into account, con-
clusions must be drawn with caution. A randomized con-
trolled trial of long-term treatment with a long-acting
opioid in chronic non-malignant pain plus or minus opioid
rescue medication is needed to inform decisions on break-
through pain management in this patient population.
Supplementary material
Table S1 and Appendices can be found as Supplementary
material in British Journal of Anaesthesia online.
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